

**Amendments to the claims**

Please amend the claims as follows. The instant listing of claims will replace all prior versions, and listings, of claims in the application:

1-10. (canceled)

11. (currently amended) A method of inducing an immune response against one or more of the group of oncogenic HPV types, the group excluding types [[HPV-]]16 and [[HPV ]]18, the method comprising administering to a subject a composition comprising an HPV16 VLP and an HPV18 VLP.

12. (currently amended) A method for preventing ~~infection and/or disease in a subject, infection, disease, or both~~, caused by one or more of the group of oncogenic HPV types, the group excluding types [[HPV]]16 and [[HPV]]18, the method comprising administering to a subject a composition comprising an HPV16 VLP and an HPV18 VLP.

13. (currently amended) The method of claim 11 [[or 12]] wherein the HPV types are selected from the group consisting of types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.

14. (currently amended) The method of ~~any of claims 11 [[- 13]]~~ claim 11 wherein the HPV types are selected from the group consisting of [[HPV]] types [[HPV]]31, [[HPV]]33, [[HPV]]35, [[HPV]]52 and [[HPV]]58.

15. (currently amended) The method of ~~any of claims 11 [[- 14]]~~ claim 11 wherein the HPV types are selected from the group consisting of [[HPV]]31, [[HPV]]35 and [[HPV]]58.

16. (currently amended) The method of ~~any of claims 11 [[- 15]]~~ claim 11 wherein the composition further comprises an adjuvant.

17. (original) The method of claim 16 wherein the adjuvant comprises an aluminum salt and 3D MPL.

18. (original) The method of Claim 17 wherein the aluminum salt is aluminum hydroxide.

19. (currently amended) A method for preventing infection of a population of subjects by one or more HPV types selected from the group consisting of oncogenic HPV types, excluding types 16 and 18, the method comprising administering to a subject a composition comprising an HPV16 VLP and an HPV18 VLP, wherein administration of the composition prevents ~~infection and/or disease~~ infection, disease, or both, in up to or at least 15% more of the population than administration of a placebo.

20. (canceled)

21. (currently amended) A vaccine composition comprising an HPV16 VLP and an HPV 18 VLP which is cross protective against ~~infection and/or disease~~ infection, disease, or both, caused by oncogenic HPV types other than type 16 and 18.

22. (New) The method of claim 12 wherein the HPV types are selected from the group consisting of types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.

23. (New) The method of claim 12 wherein the HPV types are selected from the group consisting of types 31, 33, 35, 52 and 58.

24. (New) The method of claim 12 wherein the HPV types are selected from the group consisting of 31, 35 and 58.

25. (New) The method of claim 12 wherein the composition further comprises an adjuvant.

26. (New) The method of Claim 25 wherein the adjuvant comprises an aluminum salt and 3D MPL.

27. (New) The method of Claim 26 wherein the aluminum salt is aluminum hydroxide.